Acute Exacerbations of COPD

Slides:



Advertisements
Similar presentations
Antimicrobial Prescribing in the Management of COPD
Advertisements

Chest Infections Lawrence Pike.
GOLD MANAGEMENT PLAN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
or more simply.. -asthma is a condition of paroxysmal reversible airway obstruction which is characterised by : Airflow limitation ( reversible) Airway.
ED training Respiratory/ patient with dyspnea Part 2
1 Do you vote for Penicillin? An interactive workshop on treatment of upper respiratory tract infections.
Referral to specialist respiratory service BTS guidelines, March 2008 Nawar D Bakerly.
AsthmaAsthma is a condition characterized by paroxysmal narrowing of the bronchial airways due to inflammation of the bronchi and contraction of the bronchial.
Clinical Knowledge Summaries CKS Chest infections - adults
COPD “Trying to Expire Not Expire” Dr Esyld Watson HST Emergency Medicine.
Professor of Respiratory Medicine
Managing acute exacerbations of COPD in primary care.
Applied Epidemiology Epidemiology of Chronic Obstructive Pulmonary Disease (COPD) By Chris Callan 23 April 2008.
22/06/2011.  Asthma – an introduction (Vanessa)  Diagnosis and management of chronic asthma in line with current BTS guidelines (Dr Lowery)  3 x Case.
British Guideline on the Management of Asthma. Aims Review of current SIGN/BTS guidelines –Diagnosing Asthma –Stepwise management of Asthma –Managing.
PROBLEM BASED LEARNING
Approach to bronchiectasis
1 Respiratory Diseases in HIV-infected Patients HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11 بسم الله الرحمن الرحیم با سلام.
GOLD Update 2011 Rabab A. El Wahsh, MD. Lecturer of Chest Diseases and Tuberculosis Minoufiya University REVISED 2011.
Component 1: Measures of Assessment and Monitoring n Two aspects: –Initial assessment and diagnosis of asthma –Periodic assessment and monitoring.
COPD and Outreach Services Mandy Dickson Clinical Nurse Specialist Respiratory Outreach Service.
ASSITANT PROFESSOR EAST MEDICAL WARD MAYO HOSPITAL,LAHORE
COPD Diagnosis & Management Anil Ramineni Specialist Respiratory Physiotherapist Community Respiratory Team.
Risk factors for severe disease from pandemic (H1N1) 2009 virus infection reported to date are considered similar to those risk factors identified for.
Exacerbations. Exacerbations An exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond.
Maggie Harris Independent Respiratory Nurse Specialist
Definition of asthma Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory.
Prescribing for patients with COPD Evidence Update Emma Blanden- Pharmacist.
(22%) (15%) (10%) (9%) (40%) (< 10% )
COPD Emergency Department Junior Medical Staff Teaching August 2015.
Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders;
Clinical Knowledge Summaries CKS Chest infections - adults Primary care management of acute bronchitis and community-acquired pneumonia in adults. Infective.
COPD Margarita Lianeri, PGY-2 Thursday, October 1, 2015 TOH AFHT - Melrose Clinic.
Diagnosis of asthma in adolescents and adults D.Anan Esmail Seminar Training Primary Care Asthma+ COPD
Oxygen Course.
Thank you for viewing this presentation.
Respiratory System Disorders
COPD 2003.
External multicentric validation of a COPD detection questionnaire.
Chronic Obstructive Pulmonary Disease(COPD)
Introduction to Respiratory System
Managing acute exacerbations of COPD in primary care.
STudying Acute exaceRbations and Response: The COPD STARR 2 study
Asthma-COPD Overlap Syndrome (ACOS) Challenges Diagnosing ACOS
Bronchial Asthma Dr.Radhakrishna. S. A. Bronchial Asthma Dr.Radhakrishna. S. A.
Blood eosinophil count and exacerbation risk in patients with COPD
Kyrgyz State Medical Academy
Greater Glasgow Outreach Spirometry Service: A model for closer collaboration between primary and secondary care and its impact on chronic lung disease.
COPD Dr MAMATHA SARTHI GPST3.
Prof Frank Peters Dept Family Medicine University of Pretoria
Session 4: Living with and managing nocturnal hypoventilation in MND
Disorders of the Respiratory System
COPD Exacerbations UCI Internal Medicine Mini-Lecture
PCP: Clinical Presentation
Session 3: Living with and managing nocturnal hypoventilation in MND
PCP: Clinical Presentation
COPD Exacerbation (1) C.L.I.P.S.
Dr R Nadama MD MRCP(lond) MRCP(UK), FRCP(Lond), EDARM, FCCP
West Essex Frailty Pathway: COPD
Diagnosi della BPCO 1.
Roflumilast negli studi di Fase III: i dati di efficacia
Chronic Obstructive Pulmonary Disease
COPD Chronic Obstructive Lung Disease
Algorithm for the assessment of fitness to fly in chronic obstructive pulmonary disease patients. Algorithm for the assessment of fitness to fly in chronic.
Identificazione del sottogruppo di pazienti responsivi
Dr R Nadama MD MRCP(lond) MRCP(UK), FRCP(Lond), EDARM, FCCP
COPD Chronic Obstructive Lung Disease
Shortness of breath & the child with wheeze
Presentation transcript:

Acute Exacerbations of COPD Gareth Hynes Clinical Research Fellow University of Oxford

Introduction Epidemiology Causes How to know who’s exacerbating When to use antibiotics When to use corticosteroids When to admit patients Summary

Background COPD Epidemiology 115,000 people are diagnosed with COPD each year – equivalent to a new diagnosis every 5 minutes 9% in those over age 70 Nearly 30,000 people die from COPD each year, making it the second greatest cause of death from lung disease and the UK’s fifth biggest killer

Number of People Diagnosed with COPD in the UK BLF, 2016

Background Exacerbations Median number of exacerbations seen in primary care was two per year, with one in three suffering three or more exacerbations in 1 year Frequent exacerbators (> 2 per year): Chronic sputum producers Housebound Frequent colds Poor quality of life Raised inflammatory markers when stable

Exacerbations and lung function decline The difference in the decline in FEV1 between the infrequent and frequent exacerbators was 8 ml/year, and their median exacerbation rates were 1.9 and 4.2 per year PEF did not recover to pre-exacerbation levels within 91 days in 7.1% of exacerbations.

What causes an exacerbation?

Aetiology Bafadhel, 2011

Exacerbation time course Soler-Cataluna, 2010

Diagnosing an Exacerbation An acute worsening of the patient’s usual pattern of respiratory symptoms beyond normal day-to- day variability: Increased dyspnoea Worsening cough Increased sputum volume Sputum purulence No biomarkers of an exacerbation as yet Dyspnoea: Airway narrowing Increased metabolic state Increased ventilation–perfusion mismatch.

Differential System Condition Differentiating factors Respiratory Pneumonia Pneumothorax Pleural effusion Pulmonary emboli Focal crepitations or bronchial breathing Hyperresonance and absent breath sounds Dull percussion and absent breath sounds basally Risk factors (immobility, medications), swollen calf Cardiac Congestive cardiac failure Ischaemic heart disease Arrhythmias Paroxysmal nocturnal dyspnoea, oedema Cardiac history Other Upper airway obstruction TB Stridor Country of origin, foreign travel, exposure history

Antibiotics Anthonisen et al, 1979

Antibiotics Background Van Velzen et al, 2017

Antibiotics ERS/ATS Statement 2017 Antibiotic therapy decreased treatment failure from 42% to 28% (RR 0.67) - therefore NNT to prevent one treatment failure is 7 The majority (58%) of patients improved without antibiotics, suggesting not all exacerbations require antibiotics

Antibiotics

Antibiotics Point of care CRP In the placebo arm, 77% of CRP tests resulted in concentrations < 40 mg/L. If CRP < 40, the failure rate was 12.4% If CRP > 40, the failure rate was 65.5% (P < 0.001) Miratvalles, 2013

Antibiotics The only factors significantly associated with an increased risk of failure without antibiotics were the increase in sputum purulence (OR, 6.1) and a CRP concentration ≥ 40 mg/L (OR, 13.4). When both factors were present, the probability of failure without antibiotics was 63.7%.  Predictive value for clinical failure of Anthonisen criteria (dotted line) (AUC 0.708) and with the addition of a C-reactive protein level ≥ 40 mg/L (solid line) (AUC 0.842) among patients with exacerbations of mild to moderate COPD not treated with antibiotics.

Antiobiotics Which antibiotics to use? Targeted towards previous sputum results Moraxella commonly found, Haemophilus may need longer courses (2 weeks), if Pseudomonas isolated > 1 occasion seek respiratory advice What the patient usually responds to Otherwise: Amoxicillin 500mg TDS, Co-Amoxiclav 625mg TDS, Doxycyxline 100mg OD, Clarithromycin 500mg BD

Corticosteroids NICE 2017 In the absence of significant contraindications, oral corticosteroids should be considered in all patients with significant shortness of breath which interferes with day-to-day life Prednisolone 30mg for 7 to 14 days ATS/ERS 2017 For patients with an exacerbation of COPD with suggest a short (≤ 14 days) course of prednisolone (conditional recommendation, very low quality of evidence)

Corticosteroids Bafadhel, 2012

Corticosteroids Bafadhel, 2012 Bafadhel, 2012

Admissions Major Criteria Minor Criteria Ability to cope at home Hypoxia, saturations < 90% or > 5% drop on mild exertion Severe breathlessness Altered mental state Worsening peripheral oedema Decreased level of activity LTOT Rapid onset Poor general condition Suspicion of presence of differential such as pneumonia, pneumothorax, pulmonary emboli, myocardial infarction

Summary Who to give antibiotics to? Unwell, sputum purulence, CRP > 40 Who to give corticosteroids to? Currently all In future ? high eosinophilics only Who to admit? Inability to manage at home, severe SOB, developing peripheral oedema, hypoxic Differential diagnoses PTX Pneumonia Pulmonary emboli Myocardial infarction and arrhythmia Working towards biomarker-directed approach